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Understanding the mechanism of cancer cell metastasis is
crucial for targeted cancer diagnosis and research. But this
process is still not fully understood mainly because of lack of
in vitro cell culture models that precisely mimic the physiolog-
ical complexities of cancer cell intravascular flows, invasion,
adhesion, metastasis, angiogenesis and migration to specific
sites. Micro- and nanoscale technologies offer a promising tool
for such purpose.
This special issue broadly covers the topics of cell micro-
environment, biological surface modifications, multifunction-
al nanoparticles and nanosensors, microfluidics, molecular
detection as well as multistage targeting strategies for cancer.
In particular, it focuses on investigating how we can harness
the power of micro- and nanotechnologies to radically change
the way we diagnose and treat cancer. This includes both
in vivo and ex vivo technologies. For in vivo applications,
biosensors would have the capability of detecting tumors
andmetastatic lesions that are far smaller than those detectable
using conventional technologies. Novel and multi-functional
nanodevices will be capable of detecting cancer at its earliest
stages, pinpointing its location within the body, delivering
anticancer drugs specifically to malignant cells, and determining
if these drugs are effective. In addition, functionalized nano-
particles would deliver multiple therapeutic agents to tumor sites
in order to simultaneously attack multiple points in the pathways
involved in cancer. Such nano-therapeutics are expected to in-
crease the efficacy of drugs while dramatically reducing potential
side effects. For ex vivo application, the tumor microenvironment
and circulating tumor cells can be studied. Together, such inno-
vative approaches can provide information on potential early
diagnosis as well as whether a given therapy is working as
expected.
The group of Fischbach et al. reviews recent efforts in
modulating the tumor microenvironment to develop in vitro
tumor models for cancer pathogenesis and drug discovery.
The work covers some of the recent landmark efforts towards
this direction or micro-tumor engineering with focus on tissue
microstructure organization and surrounding mass transport
behavior using biomimetic approaches. The authors thus high-
light the immense potential of microfabrication techniques for
such cancer pathogenesis applications. In order to understand
the recent advances in microfluidic technologies for cancer
research, Nagrath et al. have identified four critical areas of
research: cancer cell isolation, molecular diagnostics, tumor
biology, and high-throughput screening for therapeutics. Can-
cer cell isolation can be further subcategorized into two major
techniques: immunoaffinity-based isolation and size-based
separation. Other methods include hydrodynamic focusing
and dielectrophoresis. For the cancer cell isolation technolo-
gies, Ohnaga et al. developed polymeric microfluidic devices
for the isolation of circulating tumor cells using microposts
coated with anti-epithelial cell adhesion olecule antibody, and
a flow system to capture tumor cells using an esophageal
cancer cell line, KYSE220, dispersed in phosphate-buffered
saline or mononuclear cell separation from whole blood.
Recently, He et al. developed biocompatible nano-films com-
posed of TiO2 nanoparticles to enhance topographic interac-
tions between the nanofilm substrate surface and cell surface.
The surface of the TiO2 nanoparticles is chemically modified
to enable functionalization of anti-EpCAM antibodies. The
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design and implementation of the TiO2 nanoparticles serves to
perform enhanced immunoassay capture of cancer cells.
It was also noted that CellSearch is the only FDA ap-
proved device for isolation of circulating tumor cells (CTCs)
in metastatic breast, colon, and prostate cancers. The
CellSearch system utilizes EpCAM-coated magnetic beads
and correlation between numbers of isolated CTCs to pro-
vide prognosis in breast cancer patients. Molecular diagnos-
tics can be used to monitor biomolecules such as circulating
tumor DNA, microRNAs, proteins, and serum microvesicles.
Microfluidic devices have the capability to detect such bio-
markers with high sensitivity and accuracy. Conventional
methods, such as digital/RT-PCR (TaqMan) and mi-RNA-
profiling (Geniom Biochip), when miniaturized, enable high
throughput capabilities and parallelization. Microfluidics can
also aid in understanding tumor biology by mimicking the
physiological cues in the cellular environment through spatial
and temporal control over gradients of soluble factors and
cell–cell contacts in the extracellular matrix. In addition, the
cell culturing module can be integrated with downstream
analysis such as imaging and molecular characterization. Fi-
nally, microfluidics has the unique advantages that allow high-
throughput biomarker and drug screening.
Many groups are working towards integration of multiple
components on a single chip to allow for culture, capture,
and post capture analysis of individual cells. The following
papers present such microchip designs: Cho et al. designed a
multilevel microfluidic platform for hydrogel scaffold con-
struction in microchannels. The platform is constructed via a
rapid prototyping method based on soft lithography using
multilayered adhesive tape. The hydrogel scaffold is
designed for 3D multicellular co-culturing and anticancer
drug assays (tamixufen). Here, co-culturing of breast cancer
cells (MDA-MB-231) and fibroblasts (NIH/3T3) in separate
compartments was demonstrated with >98 % viability. Iqbal
et al. designed a tapered channel device for studying the
inhibition and migration of human glioblastoma (hGBM)
cells when they were exposed to a novel aptamer targeting
epidermal growth factor receptors (EGFR). Integration of
this system with a microscope provides real-time and quan-
titative characterization of tumor cell behavior in vitro. This
example demonstrates the capability of a microchannel de-
vice for integrated cell culturing and drug assay. White et al.
designed a novel microdevice that enables integration of the
mammosphere technique into a microsystem, thus combining it
with a number of capabilities, such as cell sorting, drug screen-
ing, and molecular assays. In this paper, a poly(dimethyl
siloxane) (PDMS) microdevice was utilized to effectively
attach and promote the formation of mammospheres. Further-
more, reagents were exchanged within the mammosphere
culture region by using a microporous membrane.
Mammospheres were shown to be successfully cultured for
ELISA testing. Li et al. designed a whole cell impedance-based
biosensor to monitor the effects of a range of different frequen-
cies at low-intensity on the growth rate of SKOV3 ovarian
cancer cells and non-cancerous HUVECs. It was found that
the growth profile of SKOV3 cells exhibited a significant
decrease with application of 200 kHz alternating electric fields
whereas HUVEC cells exhibited little to no change in growth.
This study serves to present data on inhibitory effects on
dividing cancer cells in culture in contrast to non-cancerous
cells. Such data can eventually be used in development of
methods and optimal parameters for alternating electric field
therapies in biomedical applications.
An increasingly important area of interest is to design and
optimize microfluidic microchips for cancer cell isolation. In
this special issue, Wang et al. designed and modeled
magneto-nanosensors made of arrays of GMP spin-valves
for enhanced detection of representative biomarkers, i.e.
phosphor-SMC1, GCSF, and IL-6, for radiation exposure
and cancer. The design utilized a new analytical resistive
network model to optimize a previous device design. Real-
time signals generated in the form of resistance changes of
the spin-valve sensors were induced by a magnetic field
from superparamagnetic nanoparticles. The new design
resulted in enhanced sensitivity of two to three orders of
magnitude in the detection of biomarkers. Zhang et al.
designed a microfluidic chip for the detection of CTCs
in clinical blood samples. The microchip utilized an
immunoagnetic-based approach for capturing CTCs. It
was demonstrated that the direction of RBC sedimenta-
tion relative to magnetic force required for cell separa-
tion was important for capture efficiency, throughput,
and purity. A novel flip-flop operation reduced stagna-
tion of RBCs and non-specific binding on the capture
surface by alternating the direction of magnetic field
with respect to gravity. High capture rates (more than
90 %) were achieved. In addition, the magnetic field
distribution was optimized with a smoothened magnetic
gradient within the microchannel for more uniform dis-
tribution of particles on CTC capture plane. Alternative-
ly, Luo and Qi et al. developed a cell self-loading and
patterning device for quantitatively study the effect of
density on cell behaviors. Using such model system,
they correlate the local autocrine concentration with
the tumor proliferation.
There is also an increasing interest in point-of-care detection
systems. Much effort has been directed towards the develop-
ment of inexpensive, disposable biosensor platforms using
chemical surface modifications for wide range of biomedical
applications. For example, Jon et al. designed nanobeads of
cyclic olefin copolymer (COC) plastic surfaces for multilayer-
based immunoassays. The surface of the nanobeads was chem-
ically modified to enhance specificity in the detection of bio-
molecules. Amphiphilic copolymers of hydrophobic dodecyl
or benzyl moiety, poly(ethylene glycol) (PEG), and an activated
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ester or epoxide functional group was used to coat COC sub-
strates. Assembled into multilayers, the nanobeads achieved a
dynamic range of detection (0.1 ng/mL to 1,000 ng/mL) and
enhanced detection sensitivity (0.1 ng/mL) versus conventional
detection sensitivity (10 ng/mL).
Recently, groups have studied other methods to address
the issues surrounding conventional CTC isolation methods,
such as reliance on the size and immunoaffinity of the cancer
cells. The following papers suggest other methods that over-
come these issues: Gourkutty Sanjay et al. demonstrate a
negative enrichment method which integrates WBC deple-
tion and chemical-free RBC depletion within the same setup.
The method was designed to accomplish tumor cell isolation
from blood samples with minimal sample handling and
minimal tumor cell loss without relying on cell morphology
or surface biomarkers for capture. It thus addressed two
major issues of contemporary CTC isolation techniques.
WBCs were first depleted by immunomagnetic assay,
followed by RBC depletion via microfiltration. As a result,
the method achieved > 90 % recovery of spiked tumor cells.
In order to investigate the potential of nanoscale technolo-
gies for targeted cancer drug delivery, Ramasamy et al. de-
veloped a nano-based drug delivery system. In this platform
the nanoparticles were prepared from PEG surface mod-
ified hydroxyapatite and titanium dioxide nanoparticles.
For tumor targeting, they functionalized the generated
nanoparticles with folic acid molecules. In vitro and
in vivo results show significant enhancement of paclitaxel drug
delivery efficiency in the treatment group with targeted nano
delivery system compared to the control groups. This work
illustrates the potential of nanoscale technologies for improved
cancer drug therapy.
To summarize, in this special issue we present a series of
recent papers that address the current status and fundamental
issues related to the development of multi-scale tumor
models using microfluidics and nanoscale devices, and ex-
plore novel methods on how we can harness the power of
micro- and nanotechnologies to significantly change the way
we diagnose and treat cancer.
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